Notice of Proposed Sale · 144
Kymera Therapeutics, Inc.
KYMRNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Kymera Therapeutics, Inc.
- Issuer CIK
- 0001815442
- SEC file number
- 001-39460
- Phone
- 857-285-5314
- Person for whose account securities are to be sold
- Mainolfi Nello
- Relationships to issuer
- Officer · Director
- Street
- 500 NORTH BEACON STREET, 4TH FLOOR
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 30,000 | 3,353,700.00 | 83,150,618 | 10/01/2026 | NASDAQ | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- 11 Madison Ave
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Exercise of stock options | Issuer | 30,000 | N | 10/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Nello Mainolfi | Common | 07/01/2026 | 80,000 | 9,223,529.00 |
| Nello Mainolfi | Common | 07/07/2026 | 50,000 | 5,950,000.00 |
Seller — prior-sale row 1, entry 1
- Name
- Nello Mainolfi
- Street
- 500 NORTH BEACON STREET
- Street (continued)
- 4TH FLOOR
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Seller — prior-sale row 2, entry 1
- Name
- Nello Mainolfi
- Street
- 500 NORTH BEACON STREET
- Street (continued)
- 4TH FLOOR
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ UBS Financial Services Inc, as attorney-in-fact for Nello Mainolfi
- Plan adoption dates
- 03/24/2026
Company context
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.